
News|Articles|January 1, 2008
Sapropterin (Kuvan): Synthetic form of tetrahydrobiopterin approved for the treatment of PKU
FDA approved sapropterin on December 13, 2007, to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due ro BH4-responsive phenylketonuria (PKU).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
2
Patients may not see savings from new Medicare drug programs
3
FDA accepts NDA for gedatolisib, Celcuity’s investigational breast cancer treatment
4
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
5




















































